In Brief
Refine Search
Biotechnology
Eisai has outlined the research it plans to present at the upcoming annual meeting of the American Society of Clinical Oncology. 23 May 2023
Biotechnology
ReNAgade Therapeutics, a Cambridge, USA-based company unlocking the limitless potential for RNA medicines to correct disease, today announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures. 23 May 2023
Biosimilars
The US Food and Drug Administration (FDA) has approved German family-owned drug major Boehringer Ingelheim’s Cyltezo Pen, a new autoinjector option for Cyltezo (adalimumab-adbm), an FDA-approved Interchangeable biosimilar to AbbVie’s Humira (adalimumab). 22 May 2023
Biotechnology
Japanese drugmaker Eisai has submitted to the British medicines regulator for approval for lecanemab, an Alzheimer’s med marketed in the USA by partner Biogen under the Leqembi brand. 22 May 2023
Generics
Juno Pharmaceuticals Canada has purchased Omega Laboratories, a specialist injectable pharmaceutical manufacturer in Canada, for an undisclosed sum. 19 May 2023
Pharmaceutical
Boston, USA-based Verastem Oncology will present updated interim results from Part A of the Phase II RAMP 201 study of avutometinib and defactinib at this year’s annual meeting of the American Society of Clinical Oncology (ASCO). 19 May 2023
Biotechnology
Gilead Sciences has provided an outline of 30 abstracts it will present at America’s leading cancer conference, the annual meeting of the American Society of Clinical Oncology (ASCO). 18 May 2023
Biotechnology
The non-profit Max Foundation, China-headquartered BeiGene and the BeiGene Foundation, a non-profit charitable foundation, today announced a collaboration to provide access to Brukinsa (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) in 29 low- and middle-income countries over the next three years. 17 May 2023
Pharmaceutical
Privately-held, San Diego-based Nielsen BioSciences has granted Japanese dermatology specialist Maruho exclusive rights to market CANDIN (Candida albicans skin test antigen for cellular immunity) in Japan for the treatment of Verruca vulgaris (common warts). 16 May 2023
Biotechnology
Boston, USA-based genomic medicines firm Ensoma today announced the closing of an extension of its Series B financing by $50 million, bringing the total size of the funding round to $135 million. 16 May 2023
Biotechnology
Chinook Therapeutics has entered into a collaboration with antisense specialist Ionis Pharmaceuticals in the area of rare, severe chronic kidney diseases. 16 May 2023
Pharmaceutical
Swiss financial group Cedrus is to collaborate with Chinese pharma giant Xiuzheng Pharmaceutical to identify investment opportunities in China. 16 May 2023
Biotechnology
Dutch gene therapy company uniQure has entered into a definitive agreement to sell a portion of the royalty rights due to uniQure from CSL Behring from the net sales of |Hemgenix (etranacogene dezaparvovec-drbl) to HealthCare Royalty (HCRx) and Sagard Healthcare for a gross purchase price of up to $400 million in cash. 15 May 2023
Pharmaceutical
Ireland’s health technology assessor, the National Centre for Pharmacoeconomics (NCPE), has confirmed a positive reimbursement decision for the oral anti-seizure med Ontozry (cenobamate). 15 May 2023
Pharmaceutical
Spanish plasma-derived drugmaker Grifols says that its board of directors has approved the realignment of the company’s management team to accelerate Grifols’ performance and simplify its corporate governance, ensuring a sharper focus on delivering results. 13 May 2023
Pharmaceutical
UK pharma major GSK has sold 240 million shares in its consumer healthcare spinoff business Haleon at 335 pence per share, raising about £804 million ($1 billion), the company said. 12 May 2023
Biotechnology
Positive results from the Phase III EPITOPE trial of Viaskin Peanut, a peanut allergy treatment under development by DBV Technologies, have been published in the New England Journal of Medicine. 11 May 2023
Generics
Japanese drug major Astellas Pharma today confirmed that the US Court of Appeals for the Federal Circuit (CAFC) issued a Mandate that officially ends the CAFC appeal on patent infringement of Lexiscan (regadenoson injection) 0.4mg/mL. 11 May 2023
Generics
RedHill Biopharma has published new data for its antibiotic Talicia (omeprazole/amoxicillin/rifabutin), focused on differentiating the brand from generic alternatives. 10 May 2023
Biotechnology
French biotech company Ribonexus has announced the appointment of David Howat as its new chief development officer ahead of advancing its lead product into preclinical development. 9 May 2023
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
San Diego-based Valora Therapeutics, a biotech that boasts of having a novel approach to immunotherapy, has announced the successful closing of a $30 million seed funding round. 21 November 2024
Biotechnology
Astellas Pharma has been hit by bad news from the US Food and Drug Administration, which will not currently approve the firm’s request to supplement the label for Izervay (avacincaptad pegol). 21 November 2024
article
The UK government has reappointed BioIndustry Association (BIA) chairman Daniel Mahony as its Life Sciences Investment Envoy. 21 November 2024
Pharmaceutical
Sage Therapeutics will down tools on its dalzanemdor program, after the Phase II DIMENSION trial missed both primary and secondary endpoints. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Biotechnology
HCW Biologics has announced a worldwide licensing agreement with WY Biotech to develop and commercialize one of its preclinical immunotherapy candidates. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
US clinical-stage biotech Vyriad has entered into a strategic collaboration with Swiss pharma giant Novartis to discover and develop in vivo chimeric antigen receptor (CAR) T-cell therapies. 21 November 2024
Biotechnology
The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. 20 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Pharmaceutical
Anthony Harnden has been appointed as the new chair of the UK’s Medicine and Healthcare products Regulatory Agency (MHRA). 20 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze